Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Oncology Nurses' Guide to FDA-Approved Iberdomide: Q&A With Surbhi Sidana

1 September 2026 · By · Wire by Fusion42

Published

1 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at oncnursingnews.com →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

The FDA accelerated approval of the oral CELMoD iberdomide (Zenbexus) for relapsed or refractory multiple myeloma expands treatment options and alters nursing care protocols.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You need to update nursing protocols and patient education to include iberdomide’s unique oral administration and side effect profile. The market for multiple myeloma treatment is opening to new oral therapies that change patient care dynamics.

◆ Coverage

1 source · 1 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalmultiple-myelomacelmodhealthcareoral-therapy